Harbour BioMed Licenses H2L2 Transgenic Mouse Platform to BeiGene

Harbour BioMed declared that it ventures into licensing agreement with BeiGene for producing human therapeutic monoclonal antibodies to a commercial-stage biopharmaceutical company that emphasizes on commercializing innovative immune-oncology drugs to treat cancer. Harbour Antibodies BV has granted the license.

Harbour Biomed’s transgenic H2L2 ensures biotechnology and pharmaceutical companies to enhance fresh drug development. According to the terms of the licensing agreement, BeiGene authorizes to use H2L2 platform for innumerable and varied programs for a multi-year period. Financial conditions were not revealed, however.

Dr. Jingsong Wang, CEO of Harbour BioMed claimed “Over 30 companies and academic institutions globally have licensed our transgenic mouse platforms for their fully human monoclonal antibody discovery, with several programs at the IND-ready stage, and one entered into the clinical trial.”